Zimmer Biomet Files 8-K
Ticker: ZBH · Form: 8-K · Filed: Jan 29, 2025 · CIK: 1136869
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: ZBH
TL;DR
ZBH filed an 8-K on Jan 29th for Jan 28th events - likely material info.
AI Summary
Zimmer Biomet Holdings, Inc. filed an 8-K on January 29, 2025, reporting on events that occurred on January 28, 2025. The filing includes information related to financial statements and exhibits, as well as a Regulation FD disclosure. Specific details regarding the nature of the disclosure or financial events are not provided in this excerpt.
Why It Matters
This filing indicates that Zimmer Biomet is making a material disclosure to the SEC, which could impact investor understanding of the company's current status or future plans.
Risk Assessment
Risk Level: medium — The filing of an 8-K often signifies important, potentially market-moving information, but the specific content is not detailed here, necessitating a medium risk assessment.
Key Players & Entities
- ZIMMER BIOMET HOLDINGS, INC. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- January 29, 2025 (date) — Date of Report
- 345 East Main Street (address) — Business and Mail Address
- WARSAW (location) — City
- IN (location) — State
- 46580 (zip_code) — Zip Code
FAQ
What specific event or information is being disclosed in this 8-K filing?
The provided excerpt does not specify the exact nature of the Regulation FD disclosure or the financial statements and exhibits being filed.
What is the exact date of the report filing?
The report was filed as of January 29, 2025.
What is the earliest event date reported in this filing?
The earliest event date reported is January 28, 2025.
What is the company's primary business address?
The company's business address is 345 East Main Street, Warsaw, IN 46580.
What is Zimmer Biomet's IRS Employer Identification Number?
Zimmer Biomet's IRS Employer Identification Number is 13-4151777.
Filing Stats: 1,730 words · 7 min read · ~6 pages · Grade level 14.1 · Accepted 2025-01-28 18:33:34
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ZBH New York Stock Exchan
- $13.00 — converted into the right to receive (i) $13.00 in cash, without interest and (ii) one
Filing Documents
- d644888d8k.htm (8-K) — 41KB
- d644888dex991.htm (EX-99.1) — 28KB
- d644888dex992.htm (EX-99.2) — 17KB
- g644888ex99_2p1g1.jpg (GRAPHIC) — 284KB
- g644888ex99_2p2g1.jpg (GRAPHIC) — 634KB
- g644888ex99_2p3g1.jpg (GRAPHIC) — 378KB
- g644888ex99_2p4g1.jpg (GRAPHIC) — 367KB
- g644888ex99_2p5g1.jpg (GRAPHIC) — 353KB
- g644888ex99_2p6g1.jpg (GRAPHIC) — 245KB
- g644888ex99_2p7g1.jpg (GRAPHIC) — 269KB
- g644888ex99_2p8g1.jpg (GRAPHIC) — 218KB
- g644888g0128075410514.jpg (GRAPHIC) — 5KB
- g644888g0128075410832.jpg (GRAPHIC) — 6KB
- 0001193125-25-014569.txt ( ) — 4070KB
- zbh-20250128.xsd (EX-101.SCH) — 4KB
- zbh-20250128_def.xml (EX-101.DEF) — 14KB
- zbh-20250128_lab.xml (EX-101.LAB) — 23KB
- zbh-20250128_pre.xml (EX-101.PRE) — 15KB
- d644888d8k_htm.xml (XML) — 8KB
Forward-Looking Statements
Forward-Looking Statements This communication, and any documents to which the Company refers in this communication, contain not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often include the words "forecast," "expect," "believe," "will," "intend," "plan," and words of similar substance. Such forward-looking statements include the expected completion and timing of the proposed transaction and other information relating to the proposed transaction. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or performance to differ materially from those expressed in or contemplated by the forward-looking statements, including the following: (i) risks related to the satisfaction of the conditions to closing the Merger (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as whether the stockholders of Paragon will approve the acquisition and the possibility that the acquisition does not close; (ii) risks related to the possibility that competing offers or acquisition proposal for Paragon will be made; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; (iv) risks related to the ability to realize the anticipated benefits of the Merger, including the possibility that the expected benefits from the Merger will not be realized or will not be realized within the expected time period; (v) the risk that the businesses will not be integrated successfully; (vi) risks relating to the achievement, in part or at all, of the revenue milestone necessary for the payment of any contingent value rights; (vii) disruption from the pending Merger making it more difficult to maintain business and operational relationships, including with customers,
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Joint Press Release, dated January 28, 2025 99.2 Investor Presentation, dated January 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Zimmer Biomet Holdings, Inc. Date: January 28, 2025 By: /s/ Chad F. Phipps Chad F. Phipps Senior Vice President, General Counsel and Secretary